Miller

Home

About

Miller Laboratory

Multiscale Network Biology

The lab uses computational and experimental methods to understand how mammalian cell signaling and regulation integrate across multiple scales, from the molecular to whole-body level. We combine multiplexed measurements with in vivo imaging and systems-level mathematical modeling to distill principles of cellular communication. We particularly focus on inflammation and cancer, where abnormal signals in multiple cell types promote disease progression and are therapeutically targeted.

We pursue several major goals:

Key approaches include the following:

Our interdisciplinary approach benefits from close collaboration — including with other groups in CSB — to successfully marry computational analyses with appropriate experimental measurements and models of disease.

Recent Publications (more...)

Miller MA
Nanotransfection brings progress that’s more than skin-deep
Sci Transl Med. 2017;9(405):eaao4216
Miller MA, Weissleder R
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior
Adv Drug Deliv Rev. 2017;113:61-86 - PMID: 27266447 - PMCID: PMC5136524
Miller MA
Counting on carbon quantum dots to clear infection
Sci Transl Med. 2017;9(399):eaao0969
Conrad C, Dorzweiler K, Miller MA, Lauffenburger DA, Strik H, Bartsch JW
Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis.
Fluids Barriers CNS. 2017;14(1):22 - PMID: 28806983 - PMCID: PMC5556623

Recent News (more...)

2017-08-10: CSB has been named as one of the NCI Innovative Research in Cancer Nanotechnology (IRCNs). The IRCNs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
2017-02-09: Miles Miller, PhD and Kevin King, MD, PhD have been selected to serve as Associate Scientific Advisors (ASAs) for Science's sister journal, Science Translational Medicine, for 2017-2018.